Bapineuzumab in Alzheimer's disease: where now?

  title={Bapineuzumab in Alzheimer's disease: where now?},
  author={G. K. Wilcock},
  journal={The Lancet. Neurology},
  volume={9 2},
134 Vol 9 February 2010 associated with the small sample sizes of longitudinal studies of ICH incidence. Alternatively, any reduction in ICH incidence associated with better control of blood pressure (the main causal risk factor) might have been off set by increases in cases of ICH owing to amyloid angiopathy and antithrombotic drug use among the ageing population. Another explanation might be that better control of blood pressure, smoking, diabetes, atrial fi… CONTINUE READING